Precision Medicine’s Unique Challenge
Despite significant progress, very few – if any – companies have been able to deliver on the promise of truly personalized medicine. In particular, as lackluster results from hundreds of “precision” medicine trials have demonstrated, testing for a single biomarker is more often than not an inadequate approach to select patients for desired drug response to targeted therapies.
Because the simplistic single-biomarker design used in many precision medicine clinical trials is ironically rather imprecise, poor trial results and associated financial losses often follow. Furthermore, most testing platforms used are not even capable of generating the deeper biological insight needed to identify a more complex and informed biomarker signature that could then be used to improve trial design and outcomes (Eckhardt SG, JAMA Oncology, 2018)
.
The Intersect Solution Is A Systems Biology Approach Enabled by Novel Technologies
A new-to-market class of testing technologies that integrate detection of dozens of analytes at single-cell resolution with tissue morphological context are poised to enable discovery of the next generation of precision biomarker signatures. (Galli, Eur J Immunology, 2019).
Intersect Diagnostics aims to be the leading research and development laboratory supporting biotech and pharma companies in unlocking the biomarker signatures for their drug development programs. Through design, optimization, validation, and deployment of proprietary assays on these new instruments, our goal is to help advance novel therapies toward regulatory approval.
The Intersect Approach to Precision Biomarker Signatures: Discover in 4D
